# Talazoparib molecular basket in advanced cancers

Source: https://onco.cc/trials/nct02286687/  
OnCo record `nct02286687` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This closed study tested talazoparib in advanced cancers with selected DNA-repair or PTEN alterations. Its published somatic-BRCA results come from a small mixed-cancer cohort.

## Summary

Registry active not recruiting, last updated 2026-06-12. Advanced cancers with BRCA1/2, selected other DNA-repair or PTEN alterations. The registry enrollment is estimated at 150; the 2024 publication reports 79 treated participants and 18 in the somatic BRCA1/2 cohort. These are different populations, not conflicting efficacy denominators. No current enrollment route.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Registry id: NCT02286687
- Phase: 2
- Setting: Advanced cancers with BRCA1/2, selected other DNA-repair or PTEN alterations
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT02286687: https://clinicaltrials.gov/study/NCT02286687

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Talazoparib](https://onco.cc/drugs/talazoparib/)
- key papers: [Talazoparib in advanced cancers with BRCA1/2, DNA repair and PTEN alterations](https://onco.cc/key-papers/paper-piha-paul-talazoparib-ddr-npj-2024/)

---
JSON: https://onco.cc/api/v1/entities/nct02286687.json